Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

RuiYi In-Licenses Cancer/Anti-Inflammatory mAb

publication date: Oct 5, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
RuiYi, a San Diego-Shanghai drug discovery company, has obtained world-wide rights to an IL-6 mAb from ArGEN-X, a Dutch company. The molecule is being developed as a potential treatment for cancer and inflammatory diseases. RuiYi’s operations are in Shanghai’s Zhangjiang Hi-Tech Park, while its management offices are in San Diego. RuiYi focuses its expertise on biologic drugs, using them to target G protein coupled receptors. More details....

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...